RBC Capital Maintains Sector Perform on Galapagos, Lowers Price Target to $43
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and lowers the price target from $53 to $43.
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Earnings Preview For Galapagos
Galapagos (NASDAQ:GLPG) is set to give its latest quarterly earnings report on Friday, 2023-02-24. Here’s what investors need…
Jefferies Upgrades Galapagos to Hold, Lowers Price Target to $47.2
Jefferies analyst Peter Welford upgrades Galapagos (NASDAQ:GLPG) from Underperform to Hold and lowers the price target from $49 to $47.2.
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development.
Financial Times Reported Earlier Belgian Biotech Company Galapagos on the Hunt for Deals
https://www.ft.com/content/06c089ca-8810-493d-ab40-c3fa02ff8779
Galapagos And CellPoint Presented Initial Data At ASH 2022 For GLPG5101, A CD19 CAR-T Candidate Manufactured At Point-Of-Care
6 out of 7 eligible patients with relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) responded to treatment (ORR of 86%) and all responding patients achieved complete response (CR)
No grade 3 or higher cytokine
